Avalo Therapeutics (AVTX) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 278.1% versus a gain of 0.7%. Immix Biopharma is the larger company by market cap ($770.2 million vs $720.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | IMMX |
|---|---|---|
| Share price | $13.43 | $9.29 |
| Market cap | $720.25M | $770.17M |
| 1-day change | -1.10% | -2.11% |
| YTD return | -25.22% | +81.45% |
| 1-year return | +0.74% | +278.09% |
| 5-year return | -99.79% | — |
| EPS (TTM) | $-4.31 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $15.10 |
| 52-week low | $12.51 | $2.31 |
| Distance from 52-week high | -44.66% | -38.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +228.22% | +161.57% |
| Average volume | 926.15K | 1.65M |
| Shares outstanding | 53.63M | 82.90M |
| Employees | 33 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed AVTX by 277.3 percentage points over the past year.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
AVTX vs IMMX FAQ
Which is bigger, Avalo Therapeutics or Immix Biopharma?
Immix Biopharma (IMMX) is larger, with a market capitalization of $770.17M compared with $720.25M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or IMMX?
IMMX returned +278.09% over the past 12 months, compared with +0.74% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.